== Seroconversion price (SCR) contrary to the four individual influenza infections type A and B within the group of employees who was simply vaccinated a minimum of the previous period (V), and in those that had never been vaccinated against influenza (NV)

== Seroconversion price (SCR) contrary to the four individual influenza infections type A and B within the group of employees who was simply vaccinated a minimum of the previous period (V), and in those that had never been vaccinated against influenza (NV). evaluated. After six months, antibodies declined both in combined groupings until equalize. Antibodies titers reduce with age, no distinctions were discovered among root pathologies. Adults under no circumstances vaccinated against influenza got lower seroprotection than those vaccinated previously, but influenza vaccination creates a AT-1001 more extreme serological response within them, obtaining significantly higher antibody titers than those vaccinated. The antibodies, although in lower titers, persist and equalize among both mixed groupings a minimum of six months after vaccination, which allows the given individual to end up being protected through the whole circulation from the influenza pathogen in the same season. KEYWORDS:Influenza, vaccine, vaccination, adults, workers == Introduction == Influenza is a viral infectious disease that causes around 35 million hospitalizations per year and 650,000 deaths worldwide.1However, these values are underestimated because influenza plays an essential role in the development and evolution of other pathologies, such as cardiovascular diseases, on which it has a direct and indirect impact.2 The best way to prevent influenza is vaccination. There are different approaches to influenza vaccination. One approach is universal vaccination, such as the United States & Canada.3,4Another Mouse monoclonal to GATA3 approach is vaccination focused on the most vulnerable people,5,6such as elderly, pregnant women and patients with underlying diseases.7A third approach is vaccination focused on workers in professions AT-1001 with a higher probability of contact with the most vulnerable people or zoonotic sources of influenza. An example is Spain, where health care workers (hospitals, pharmacies, nursing homes, social and health care centers, etc.), state security forces and corps, firemen, civil protection, health emergencies, and also farmers who are exposed to domestic fowl or pigs in poultry and livestock farms.7However, workers of other types can have recourse to influenza vaccination through their companys occupational risk prevention services. Although this practice is not very common, large companies carry out vaccination campaigns that bring the vaccine to the worker, and not the worker to the vaccine. This is important because some studies postulate that vaccination in the workplace has a clear impact in reducing the intensity of influenza epidemics.8At the same time, the low vaccine acceptability in adults makes it difficult to carry out serological and vaccine efficacy studies in this age group, since access to this type of samples is not easy and requires optimized logistics. The aim of our study is to know the dynamics of the antibody response to influenza after vaccination of two groups of workers, one of whom had been vaccinated in the previous season, and another who had never been vaccinated against influenza. == Materials and methods == == Study design == We designed a case-cohort study including workers between 18 and 65 years of age, from two automobile factories in Spain (Renault Espaa S.A., hereinafter The company) in the cities of Valladolid and Palencia, who were vaccinated against influenza in the 20212022 season. To carry out this study, we included all individuals who agreed to participate in the study, the only exclusion criterion being the impossibility of being vaccinated against influenza due to the existence of contraindications. Recruitment was carried out by means of an appeal through e-mails and publicity about the vaccination campaign to all the workers of both factories (n= 8,043), carried out by the company. A total of 822 workers (10.2%) finally attended the vaccination, of whom 550 (66.9%) had been vaccinated against influenza at least the previous season (group V), and 272 (33.1%) had never been vaccinated against influenza previously (group NV). The vaccine (FluarixTetra, GSK) was administered by the companys medical team in both factories. The vaccine administered contained the influenza A and B strains recommended by WHO for vaccination in the 20212022 season for the northern hemisphere grown in egg (A(H1N1)pdm09, A/Victoria/2570/2019; A(H3N2), A/Cambodia/e0826360/2020; B/Victoria, B/Washington/02/2019; B/Yamagata, B/Phuket/3073/2013).9 The companys medical team collected a serum sample from each worker on the day of vaccination, an additional sample 3040 days after vaccination and another sample 6 months after vaccination. The samples were sent to the National Influenza Center in Valladolid for serological analysis against the four human influenza AT-1001 viruses. In addition, during the first sample collection, the medical team collected information on sociodemographic variables (age and sex), history of influenza vaccination (Yes/No) and the existence of underlying diseases, which were differentiated into five different.